Gabelli Funds’s Myriad Genetics MYGN Stock Holding History

Gabelli Funds’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,000	Closed	-$206K	–	1157
2016 Q3	$206K	Sell	10,000 -150,000	-94%	-$3.8M	﹤0.01%	1119
2016 Q2	$4.9M	Buy	160,000 +500	+0.3%	+$17.4K	0.03%	557
2016 Q1	$5.97M	Hold	159,500	–	–	0.04%	499
2015 Q4	$6.88M	Hold	159,500	–	–	0.04%	467
2015 Q3	$5.98M	Hold	159,500	–	–	0.04%	513
2015 Q2	$5.42M	Buy	159,500 +40,000	+33%	+$1.36M	0.03%	563
2015 Q1	$4.23M	Buy	119,500 +96,500	+420%	+$3.45M	0.02%	626
2014 Q4	$783K	Sell	23,000 -7,000	-23%	-$248K	﹤0.01%	924
2014 Q3	$1.16M	Buy	+30,000	New	+$1.12M	0.01%	861

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gabelli Funds's MYGN Position: Q4 2016 in Review

Gabelli Funds sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 10,000 shares — an estimated $206K sold.

Gabelli Funds first reported a position in MYGN in Q3 2014 and held it in 9 quarters. The position peaked at $6.88M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

Gabelli Funds reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
Gabelli Funds sold 10,000 Myriad Genetics shares in Q4 2016, an estimated $206K.
Gabelli Funds first reported a position in Myriad Genetics in Q3 2014 and held it in 9 quarters.
Gabelli Funds's Myriad Genetics position peaked at $6.88M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Gabelli Funds's 13F filing for Q4 2016, filed 10 Feb 2017.